Cargando…

Clinical characteristics and prognosis of 16 relapsed/refractory B-cell malignancy patients with CAR T-cell-related hyperferritinaemia

With the success of chimeric antigen receptor-modified (CAR) T-cell therapy for relapsed/refractory (r/r) B-cell malignancies, severe complications after CAR T-cell infusion have emerged as nonnegligible prognosis-related factors. However, the prognosis of patients with CAR T-cell-related hyperferri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Lanlan, Yu, Nanzhou, Li, Tongjuan, Ji, Hongyan, Jiang, Lijun, Wang, Di, Xu, Bin, Zhou, Xiaoxi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600326/ https://www.ncbi.nlm.nih.gov/pubmed/36313658 http://dx.doi.org/10.3389/fonc.2022.912689

Ejemplares similares

A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy
por: Li, Tongjuan, et al.
Publicado: (2019)

CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain
por: Li, Tongjuan, et al.
Publicado: (2020)

Consensus Statement on the definition and classification of metabolic hyperferritinaemia
por: Valenti, Luca, et al.
Publicado: (2023)

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
por: Zhang, Ying, et al.
Publicado: (2021)

New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Wang, Linqin, et al.
Publicado: (2021)

Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
por: Cheng, Jiali, et al.
Publicado: (2019)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023)

Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy
por: Vercellino, Laetitia, et al.
Publicado: (2021)

Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report
por: Liu, Wanying, et al.
Publicado: (2022)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia
por: Giglio, Fabio, et al.
Publicado: (2023)

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
por: Shah, Nirav N., et al.
Publicado: (2019)

Successful Treatment of Refractory and Relapsed CNS Acute Lymphoblastic Leukemia With CD-19 CAR-T Immunotherapy: A Case Report
por: Htun, Kyaw Thu, et al.
Publicado: (2021)

CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results
por: Li, Zhihui, et al.
Publicado: (2023)

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
por: Li, Chunrui, et al.
Publicado: (2021)

Hyperferritinaemia in Dengue Virus Infected Patients Is Associated with Immune Activation and Coagulation Disturbances
por: van de Weg, Cornelia A. M., et al.
Publicado: (2014)

Hyperferritinaemia-cataract syndrome: Worldwide mutations and phenotype of an increasingly diagnosed genetic disorder
por: Millonig, Gunda, et al.
Publicado: (2010)

Polymyxin B haemoperfusion treatment for respiratory failure and hyperferritinaemia due to COVID‐19
por: Ishiwari, Mayuko, et al.
Publicado: (2020)

Radiopharmaceuticals for Relapsed or Refractory Leukemias
por: Kunos, Charles A., et al.
Publicado: (2019)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
por: Jacoby, Elad
Publicado: (2019)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2020)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
por: Meier, Jeremy A., et al.
Publicado: (2022)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
por: Rentsch, Vera, et al.
Publicado: (2022)

Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
por: Zhang, Xiaohui, et al.
Publicado: (2023)

Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers
por: Kunos, Charles A., et al.
Publicado: (2019)

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
por: Zhu, Haibo, et al.
Publicado: (2021)

Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
por: Han, Lu, et al.
Publicado: (2021)

Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy
por: Ding, Shuyi, et al.
Publicado: (2023)

Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk
por: Lyu, Cuicui, et al.
Publicado: (2021)

Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy
por: Li, Tongjuan, et al.
Publicado: (2020)

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
por: Li, Jia, et al.
Publicado: (2021)

Characteristics of recurrence, predictors for relapse and prognosis of rapid relapse triple-negative breast cancer
por: Cai, Shuang-Long, et al.
Publicado: (2023)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
por: Liu, Weiping, et al.
Publicado: (2021)

CAR T-cell therapy for triple-class exposed relapsed/refractory multiple myeloma
por: Cavo, Michele
Publicado: (2023)

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
por: Lee, Boram, et al.
Publicado: (2021)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

Treatment selection for patients with relapsed or refractory follicular lymphoma
por: Skarbnik, Alan Z., et al.
Publicado: (2023)

P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA
por: Luo, Wenjing, et al.
Publicado: (2023)

Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia
por: Zheng, Qingqing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b62dvicb47abiqgvrbdgida2n4